sur ABIVAX (EPA:ABVX)
Abivax Appoints Mark Stenhouse as Observer and Strategic Advisor
On November 13, 2024, Abivax announced the appointment of Mark Stenhouse as a Board Observer and Advisor. Former COO of Prometheus, recently acquired by Merck for $10.8 billion, Stenhouse has over 30 years of experience in the biopharmaceutical industry. Prior to Prometheus, he was Vice President, Immunology at AbbVie, overseeing HUMIRA® in the United States.
Marc de Garidel, CEO of Abivax, expressed his satisfaction with this appointment, highlighting Stenhouse's expertise as an asset for the progression of Abivax's projects, including the development of Obefazimod. Stenhouse is enthusiastic and welcomes Obefazimod's potential to address unmet therapeutic needs in the medical community.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX